Kyverna Therapeutics, Inc. - 8-K Filing
Kyverna Therapeutics appointed Gregory Martini as Chief Financial Officer effective May 18, 2026. Martini previously served as CFO of Ironwood Pharmaceuticals and will receive a base salary of $525,000, an annual performance bonus target of 40% of his base salary (pro-rated for 2026), and a sign-on bonus of $300,000. He also received an option to purchase 325,000 shares under the company's equity plan. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 8.01 Other Events, 9.01 Financial Statements and Exhibits(d) Exhibits)
Tickers: $KYTX